Key clinical point:
Major finding: The 2-year leukemia-free survival was about 70% in patients in first remission who received haplo-HSCT vs. 40% in patients who received chemotherapy.
Study details: A prospective multicenter trial of 112 adult patients with acute lymphocytic leukemia.
Disclosures: Dr. Lv reported having no financial disclosures.
Lv M et al. TCT 2019, Abstract 8.